Skip Navigation


NDT Advance Access originally published online on November 26, 2007
Nephrology Dialysis Transplantation 2008 23(3):1061-1064; doi:10.1093/ndt/gfm824
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/3/1061    most recent
gfm824v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Clajus, C.
Right arrow Articles by Kielstein, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clajus, C.
Right arrow Articles by Kielstein, J. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Acute kidney injury due to deferoxamine in a renal transplant patient

Christian Clajus1, Jan U. Becker2, Dirk O. Stichtenoth3, Jessica Wortmann1, Anke Schwarz1 and Jan T. Kielstein1

1 Department of Nephrology, Hannover Medical School, Hannover, Germany 2 Institute for Pathology, Hannover Medical School, Hannover, Germany 3 Institute for Clinical Pharmacology, Hannover Medical School, Hannover, Germany

Jan T. Kielstein, Department of Internal Medicine, Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. Tel: +49–511–532 6319; Fax: +49–511–55 23 66; E-mail: Kielstein@yahoo.com

Keywords: chronic kidney disease; deferoxamine; renal biopsy; toxicity

The first 10% of the full text of this article appears below.



   Introduction
 
Deferoxamine is an iron-chelating agent, used in the treatment of acute iron intoxication and chronic iron overload secondary to multiple blood transfusions. Moreover it is currently recommended by the K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease (CKD) for treatment in symptomatic aluminium toxicity [1]. Deferoxamine is known to have many adverse effects, some of them potentially fatal, especially infections with siderophilic organisms like mucormycosis [2]. We report a case of acute tubular injury in a renal transplant recipient secondary to treatment with deferoxamine due to iron overload, in the context of autoimmune haemolytic anaemia.



   Case report
 
A 58-year-old Caucasian male, with 21-year status post-cadaver kidney transplantation due to Goodpasture's syndrome, presented with a sudden rise in serum creatinine from 120 µmol/L to 250 µmol/L (Figure 1. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
C. Clajus, J. U. Becker, D. O. Stichtenoth, J. Wortmann, A. Schwarz, and J. T. Kielstein
Reply
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2705 - 2705.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Hirschberg, W. Bennett, J. Scheinman, R. Coppo, and C. Ponticelli
Acute kidney injury due to deferoxamine in a renal transplant patient
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2704 - 2705.
[Full Text] [PDF]